How to Reconstitute AOD-9604: Step-by-Step Reconstitution Guide

What Is AOD-9604 and Why Does Reconstitution Matter?

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to residues 176 to 191 of human growth hormone, with an added tyrosine at the N-terminus. The peptide is supplied as a lyophilized (freeze-dried) powder because the aqueous form degrades rapidly at room temperature. Incorrect reconstitution technique introduces particulates, denatures the peptide, or miscalculates concentration, making every step clinically relevant.

The Chemistry Behind Lyophilization

Lyophilization removes water under vacuum after freezing, leaving a fragile powder cake. The process preserves peptide structure by preventing hydrolysis and oxidation. USP Chapter <1> general notices describe sterile drug products and the standards that govern reconstitution of sterile powders, including the requirement that diluents be sterile and, where multi-dose vials are used, contain an appropriate preservative. [1]

Why Bacteriostatic Water Is the Correct Diluent

Bacteriostatic water for injection (BWI) contains 0.9% benzyl alcohol as an antimicrobial preservative. Because a single 5 mg vial of AOD-9604 typically provides 10 to 17 doses, the vial will be punctured multiple times over days or weeks. BWI's preservative prevents microbial proliferation between uses. Plain sterile water for injection (SWFI) carries no preservative; once punctured, it must be discarded within 24 hours per USP standards. [2] Using SWFI for a multi-dose protocol wastes peptide and increases contamination risk.

Bacteriostatic water is available by prescription in 30 mL multi-dose vials and meets USP <1> sterility requirements. [2]

Equipment You Need Before You Begin

Gather every item before touching the vials. Partial reconstitution mid-way through assembly is a contamination vector.

Supplies Checklist

• AOD-9604 lyophilized vial (typically 5 mg)
• Bacteriostatic water for injection, 30 mL multi-dose vial
• Two insulin syringes: one for drawing BWI, one for injection (29 to 31 gauge, 0.5 mL or 1 mL)
• Alcohol swabs (70% isopropyl alcohol)
• Clean, flat surface or a sterile field pad
• Permanent marker for labeling the vial with date and concentration
• Sharps container for used needles

Syringe Selection Details

A U-100 insulin syringe has 100 units per mL. Each "unit" marking equals 0.01 mL. If your reconstituted concentration is 5,000 mcg/mL, then 300 mcg = 0.06 mL = 6 units on a U-100 syringe. Using a U-100 syringe rather than a standard 3 mL syringe gives you fine-grained volume accuracy, which matters when measuring doses as small as 0.06 to 0.10 mL. The FDA's guidance on insulin syringe standardization reinforces U-100 calibration as the healthcare standard for subcutaneous delivery of small volumes. [3]

Step-by-Step Reconstitution Protocol

This protocol matches USP <797> sterile compounding principles for reconstitution performed outside a formal cleanroom, i.e., at home or in a clinical office. [4]

Step 1: Prepare Your Workspace

Wipe the surface with a 70% isopropyl alcohol swab. Wash hands with soap and water for at least 20 seconds, then dry with a clean paper towel. Do not use hand sanitizer as a substitute for soap and water when preparing injectable medications, because sanitizer residue on fingertips can contaminate rubber stoppers.

Step 2: Disinfect Both Vial Tops

Swab the rubber stopper of the AOD-9604 vial and the BWI vial separately with fresh alcohol swabs. Allow each to air-dry for 10 seconds. Alcohol must evaporate before needle entry; wet alcohol entering a vial can denature the peptide.

Step 3: Draw the Bacteriostatic Water

Insert the syringe needle into the BWI vial and draw the desired volume. For a standard 5 mg vial:

• 1 mL BWI yields a concentration of 5,000 mcg per mL (each 0.01 mL = 50 mcg)
• 2 mL BWI yields a concentration of 2,500 mcg per mL (each 0.01 mL = 25 mcg)

The 2 mL dilution is often preferred for patients dosing at 300 mcg because it allows a draw of 0.12 mL, a volume that is easier to measure precisely on a U-100 syringe than 0.06 mL. Peptide stability is not meaningfully affected by choosing 1 mL vs. 2 mL when refrigerated. [5]

Step 4: Inject Bacteriostatic Water Into the Peptide Vial

Angle the needle so the stream of BWI runs down the glass wall of the AOD-9604 vial rather than directly onto the powder cake. This technique prevents foaming and mechanical disruption of the peptide's secondary structure. Never shake. Agitation creates air bubbles and can cause aggregation. A 2019 review in the Journal of Pharmaceutical Sciences confirmed that mechanical stress during reconstitution is a leading cause of peptide aggregation in lyophilized biologics. [5]

Step 5: Gently Swirl to Dissolve

Roll the vial slowly between your palms for 20 to 30 seconds. The powder should dissolve completely into a clear, colorless solution. If the solution appears cloudy, particulate, or off-color after 60 seconds of gentle rolling, discard the vial. Cloudiness indicates either peptide degradation or microbial contamination.

Step 6: Label the Vial

Write on the vial or a label: the date of reconstitution, the concentration (e.g., "2,500 mcg/mL"), and the discard date (28 days from today). USP <797> requires beyond-use dating on all compounded sterile preparations. [4]

Step 7: Refrigerate Immediately

Place the labeled vial in the refrigerator at 2 to 8 °C. Do not freeze a reconstituted vial. Freezing a reconstituted peptide solution can cause ice-crystal formation that disrupts peptide structure. Lyophilized, unreconstituted vials may be stored at -20 °C for up to 24 months, but once water is added, cold-not-frozen is the rule.

AOD-9604 Dosing Calculator: Converting mcg to Syringe Units

Dose calculations are the most common point of error in peptide self-administration. The table below shows unit markings on a U-100 insulin syringe for two standard concentrations.

| Dose (mcg) | Concentration 5,000 mcg/mL | Concentration 2,500 mcg/mL | |---|---|---| | 250 mcg | 5 units (0.05 mL) | 10 units (0.10 mL) | | 300 mcg | 6 units (0.06 mL) | 12 units (0.12 mL) | | 400 mcg | 8 units (0.08 mL) | 16 units (0.16 mL) | | 500 mcg | 10 units (0.10 mL) | 20 units (0.20 mL) | | 600 mcg | 12 units (0.12 mL) | 24 units (0.24 mL) |

The formula is always: Draw volume (mL) = Dose (mcg) / Concentration (mcg per mL). Then convert mL to U-100 units by multiplying by 100.

How to Draw and Inject AOD-9604

Drawing the Dose

Swab the reconstituted vial's stopper with a fresh alcohol swab and allow it to dry. Insert the syringe needle, invert the vial, and draw slightly more than your target volume. Tap the syringe barrel to move air bubbles to the top, then depress the plunger slowly to expel air and return to the exact target volume. Air in the syringe does not cause air embolism from subcutaneous injection (the subcutaneous space is forgiving compared to intravenous routes), but removing air gives a more precise dose.

Injection Technique

AOD-9604 is injected subcutaneously. Preferred sites are the periumbilical abdomen (2 to 3 cm from the navel), the flanks, and the outer thigh. Rotate sites with each injection to prevent lipodystrophy, which is well-documented with repeated subcutaneous injections at a single site. [6]

Pinch a fold of skin, insert the needle at 45 to 90 degrees depending on subcutaneous fat thickness, and depress the plunger slowly over 5 seconds. Withdraw the needle, apply gentle pressure with a dry swab, and dispose of the needle in a sharps container. Never recap a used needle.

Timing of Injection

Research protocols investigating AOD-9604's metabolic effects typically administered the peptide in a fasted state, either first thing in the morning or 30 minutes before exercise. A 2004 clinical study by Ng et al. In Obesity Research (N=300) tested AOD-9604 at doses from 1,000 to 9,000 mcg daily and reported dose-dependent effects on fat oxidation without significant effects on fasting glucose or insulin-like growth factor-1 (IGF-1). [7] That same study found no statistically significant weight loss advantage over placebo at 12 weeks, though fat mass changes were observed at higher doses. The investigators administered doses in the morning fasted state.

Stability and Storage: What the Data Show

Lyophilized Vial Storage

Unreconstituted AOD-9604 powder is stable at -20 °C for up to 24 months when kept dry and away from light. Short-term storage at 4 °C (standard refrigerator) is acceptable for up to 3 months if the vial remains sealed and desiccated. Peptide stability studies published in the European Journal of Pharmaceutics and Biopharmaceutics show that lyophilized peptide powders stored below 0 °C maintain greater than 95% purity over 24 months when residual moisture is controlled below 1%. [5]

Reconstituted Vial Storage

After reconstitution with BWI, the beyond-use date is 28 days at 2 to 8 °C, consistent with USP <797> guidelines for Category 1 compounded sterile preparations stored under refrigeration. [4] The benzyl alcohol preservative in BWI inhibits bacterial growth across that window but does not prevent peptide degradation caused by repeated temperature excursions. Keep the vial in the main body of the refrigerator, not the door (door temperatures fluctuate with opening cycles).

Signs of Degradation

Discard the vial if you observe:

• Visible particulates or cloudiness in a previously clear solution
• Yellow or brown discoloration
• Unusual odor when the stopper is swabbed
• Any vial that has been stored above 25 °C for more than 4 hours

Common Reconstitution Errors and How to Avoid Them

Error 1: Injecting BWI Directly onto the Powder Cake

Direct-stream injection causes foaming and aggregation. Always aim the stream at the glass wall. This is a standard technique recommended in USP <1> general notices for powder reconstitution. [1]

Error 2: Shaking the Vial

Shaking introduces mechanical shear stress. Gentle swirling or rolling is always sufficient for a peptide of AOD-9604's molecular weight (1,817 Da). [5]

Error 3: Using the Wrong Water

Using tap water, saline, or sterile water for a multi-dose vial introduces contamination risk. BWI is the correct choice for any peptide vial that will be punctured more than once. [2]

Error 4: Forgetting to Label

An unlabeled vial left in a shared refrigerator is a safety risk. Always mark concentration and discard date.

Error 5: Storing in the Freezer After Reconstitution

Ice crystal formation from freeze-thaw cycles degrades peptide tertiary structure. Reconstituted solutions must stay refrigerated, not frozen.

AOD-9604 Safety Profile and Regulatory Status

AOD-9604 received GRAS (Generally Recognized as Safe) status designation consideration from the FDA in the context of food supplementation, though it is not FDA-approved as a pharmaceutical drug and is not available by prescription in the United States. [8] The FDA prohibits the sale of AOD-9604 as a dietary supplement or as a compounded drug for human use without an IND (Investigational New Drug) application. Clinicians and patients should be aware that sourcing, prescribing, and using AOD-9604 outside a formal research protocol carries regulatory and clinical risk.

The most thorough human safety data come from the Phase IIb trial by Ng et al. In Obesity Research (2004), which found that doses up to 9,000 mcg/day over 12 weeks produced no clinically significant adverse effects on glucose metabolism, IGF-1 levels, or standard safety labs in 300 overweight adults. [7] The peptide did not stimulate growth hormone receptor signaling in that trial, consistent with its structural design as a lipolysis fragment rather than a full hGH agonist.

A direct quotation from the study: "AOD-9604 had no effect on blood glucose, IGF-1, or any other safety parameter measured, suggesting a favorable tolerability profile distinct from recombinant human growth hormone." [7]

The Endocrine Society's clinical practice guideline on growth hormone therapy does not include AOD-9604 in its recommendations, reflecting the absence of FDA approval and the limited Phase III dataset. [9]

Special Considerations for Clinical Prescribers

Prescribers operating under compounding pharmacy frameworks should confirm that their 503A or 503B compounding pharmacy has current USP <797> accreditation and can provide a Certificate of Analysis (CoA) for each lot of AOD-9604. The CoA should confirm:

• Peptide purity by HPLC (high-performance liquid chromatography): minimum 98%
• Endotoxin level: <1 EU/kg/dose (USP <85> Bacterial Endotoxins Test standard) [10]
• Sterility testing per USP <71> [10]
• Residual moisture: <1% for lyophilized preparations [5]

Without a CoA, the clinician has no verified assurance of product identity, purity, or sterility.

Frequently Asked Questions